Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study

This is the authors' abstract. We don't add key points for this paper.

Pralsetinib, a selective RET targeted tyrosine kinase inhibitor (TKI), has been approved for treating locally advanced or metastatic RET fusion-positive NSCLC in adults who have previously received platinum-based chemotherapy in China.